Psilera
Tampa
About Psilera
Psilera develops therapies aimed at neurological and psychiatric disorders by leveraging neuroplastogens, compounds that promote brain plasticity without hallucinogenic effects. The company builds a proprietary library of serotonergic compounds and applies computational tools to design molecules for conditions such as alcohol use disorder and frontotemporal dementia. Its research pipeline emphasizes non-hallucinogenic derivatives of psychedelic compounds to provide safe and scalable treatment options. Psilera integrates medicinal chemistry, neuroscience, and pharmacology to create small-molecule drugs that address unmet medical needs. Through this approach, the company seeks to expand treatment possibilities for patients facing hard-to-treat neurological conditions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $7.6M
- Last round: Grant (Oct 2025)
- Website: psilera.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Mental Health, Neuroscience, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/psilera-43122 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.